

## CLAIMS

I claim:

1. A vaccine comprising:  
*Subj* a pharmaceutical composition comprising isolated and purified cell surface adhesin protein obtained from a *Candida* strain.
2. The vaccine of Claim 1, wherein the cell surface adhesin protein is *Candida albicans* ALS1 adhesion protein (Als1p).
3. The vaccine of Claim 2, wherein the protein is a fragment encompassing the N-terminus of Als1p and containing the adhesin binding site.
4. The vaccine of Claim 1, wherein said cell surface adhesin protein is derived from a Candidal strain selected from the group consisting of *Candida krusei*, *Candida tropicalis*, and *Candida parapsilosis*.
5. A method for treatment and prevention of disseminated candidiasis, comprising:  
10 administering a vaccine comprised of a pharmaceutically effective amount of an ALS1 adhesion protein of *Candida albicans* in an amount elicit to an immune response.
6. The method of Claim 5, wherein said step of administering vaccine comprises the step of using active immunization through administration of the *Candida albicans* ALS1 gene product.
- 20 7. The method of Claim 5, wherein said step of administering vaccine comprises passive immunization through administration of antiserum to ASL1 gene product.

8. ~~The method of Claim 5, wherein said step of administering vaccine further comprises the step of using a combination of active immunotherapy with the ALS1 gene product and passive immunotherapy with antiserum to the ALS1 gene product.~~

and  
B8

RECORDED IN U.S. PATENT AND TRADEMARK OFFICE  
RECORDED IN U.S. PATENT AND TRADEMARK OFFICE